{Reference Type}: Journal Article
{Title}: Targeting sgRNA N secondary structure as a way of inhibiting SARS-CoV-2 replication.
{Author}: Baliga-Gil A;Soszynska-Jozwiak M;Ruszkowska A;Szczesniak I;Kierzek R;Ciechanowska M;Trybus M;Jackowiak P;Peterson JM;Moss WN;Kierzek E;
{Journal}: Antiviral Res
{Volume}: 228
{Issue}: 0
{Year}: 2024 Aug 24
{Factor}: 10.103
{DOI}: 10.1016/j.antiviral.2024.105946
{Abstract}: SARS-CoV-2 is a betacoronavirus that causes COVID-19, a global pandemic that has resulted in many infections, deaths, and socio-economic challenges. The virus has a large positive-sense, single-stranded RNA genome of ∼30 kb, which produces subgenomic RNAs (sgRNAs) through discontinuous transcription. The most abundant sgRNA is sgRNA N, which encodes the nucleocapsid (N) protein. In this study, we probed the secondary structure of sgRNA N and a shorter model without a 3' UTR in vitro, using the SHAPE (selective 2'-hydroxyl acylation analyzed by a primer extension) method and chemical mapping with dimethyl sulfate and 1-cyclohexyl-(2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate. We revealed the secondary structure of sgRNA N and its shorter variant for the first time and compared them with the genomic RNA N structure. Based on the structural information, we designed gapmers, siRNAs and antisense oligonucleotides (ASOs) to target the N protein coding region of sgRNA N. We also generated eukaryotic expression vectors containing the complete sequence of sgRNA N and used them to screen for new SARS-CoV-2 gene N expression inhibitors. Our study provides novel insights into the structure and function of sgRNA N and potential therapeutic tools against SARS-CoV-2.